服务热线
400-611-2850
百替医学是国内首家专注于医学科研咨询及技术服务的公司,专门为临床医生提供科研问题解决方案。
Phone: 400-611-2850
E-mail:: service@100biotech.com
或 在线留言 给我们
1、联系与咨询。
您可通过公司的服务热线400-611-2850和服务邮箱 service@100biotech.com,或者与您联系的百替医学服务人员,告知您的科研服务需求2、签订保密协议,洽谈具体服务内容。
在双方签订合作保密协议后,您可与百替医学科研服务咨询小组进行具体项目沟通;您和百替医学双方明确服务产品需求和具体项目要求;百替医学制作和提交项目实施方案和报价。3、双方签订合同,客户按合同支付费用。
双方对合同服务内容和价格无异议后,签订服务合同。您按合同约定支付费用,并提供必要的实验药品或样品(实验样品的寄送须采用特快专递形式邮寄,有低温要求的、固定要求的,按低温保存、固定防碎方法运输,以确保安全可靠)。4、项目实施,开始为客户提供科研咨询和技术服务。
百替医学按合同方案进行项目实施。项目实施过程中,百替医学项目经理按时与客户反馈及交流信息;百替医学开始为客户提供相关科研咨询和技术服务,并及时按合同将数据、材料、样本、模型等相关信息材料提供给客户。5、分析结果资料,整理提交数据。
百替医学技术团队分析整理数据,总结结论,将完整项目实施报告和数据、图片等相关信息提供给客户,同时根据合同处理相关的实验材料。项目报告内容将包括具体实验方法、步骤、所用试剂、仪器、数据、结果和结论等。6、项目完成,协商进一步合作。
项目完成,客户如有后续科研服务需求,双方协商进一步合作。
糖尿病治疗现重大突破
发布时间:2014-07-22 00:00 文章来源: 作者:
微评:7月17日出版的《Nature》上刊载了一则令人振奋的消息:只需对饲料诱导的糖尿病小鼠(相当于人2型糖尿病)注射一针成纤维细胞生长因子1(FGF1),就能在48小时内让血糖恢复正常水平!如果持续注射,还能逆转胰岛素抵抗。由于FGF1是人体自身分泌的成分,这种治疗方法不会带来任何副作用。
课题组即将开展临床实验,以评估FGF1是否对人2型糖尿病具有同等治疗作用。如该治疗方法最终被确定为可行,将是糖尿病医疗领域的一项重大突破。
以下是刊载于《Nature》上的原文:
In mice with diet-induced diabetes -- the equivalent of type 2 diabetes in humans -- a single injection of the protein FGF1 is enough to restore blood sugar levels to a healthy range for more than two days. The discovery by Salk scientists, published today in the journal Nature, could lead to a new generation of safer, more effective diabetes drugs.
The team found that sustained treatment with the protein doesn't merely keep blood sugar under control, but also reverses insulin insensitivity, the underlying physiological cause of diabetes. Equally exciting, the newly developed treatment doesn't result in side effects common to most current diabetes treatments.
"Controlling glucose is a dominant problem in our society," says Ronald M. Evans, director of Salk's Gene Expression Laboratory and corresponding author of the paper. "And FGF1 offers a new method to control glucose in a powerful and unexpected way."
Type 2 diabetes, which can be brought on by excess weight and inactivity, has skyrocketed over the past few decades in the United States and around the world. Almost 30 million Americans are estimated to have the disease, where glucose builds up in the bloodstream because not enough sugar-carting insulin is produced or because cells have become insulin-resistant, ignoring signals to absorb sugar. As a chronic disease, diabetes can cause serious health problems and has no specific cure. Rather it is managed -- with varying levels of success -- through a combination of diet, exercise and pharmaceuticals.
Diabetes drugs currently on the market aim to boost insulin levels and reverse insulin resistance by changing expression levels of genes to lower glucose levels in the blood. But drugs, such as Byetta, which increase the body's production of insulin, can cause glucose levels to dip too low and lead to life-threatening hypoglycemia, as well as other side effects.
In 2012, Evans and his colleagues discovered that a long-ignored growth factor had a hidden function: it helps the body respond to insulin. Unexpectedly, mice lacking the growth factor, called FGF1, quickly develop diabetes when placed on a high-fat diet, a finding suggesting that FGF1 played a key role in managing blood glucose levels. This led the researchers to wonder whether providing extra FGF1 to diabetic mice could affect symptoms of the disease.
Evans' team injected doses of FGF1 into obese mice with diabetes to assess the protein's potential impact on metabolism. Researchers were stunned by what happened: they found that with a single dose, blood sugar levels quickly dropped to normal levels in all the diabetic mice.
"Many previous studies that injected FGF1 showed no effect on healthy mice," says Michael Downes, a senior staff scientist and co-corresponding author of the new work. "However, when we injected it into a diabetic mouse, we saw a dramatic improvement in glucose."
The researchers found that the FGF1 treatment had a number of advantages over the diabetes drug Actos, which is associated with side effects ranging from unwanted weight gain to dangerous heart and liver problems. Importantly, FGF1 -- even at high doses -- did not trigger these side effects or cause glucose levels to drop to dangerously low levels, a risk factor associated with many glucose-lowering agents. Instead, the injections restored the body's own ability to naturally regulate insulin and blood sugar levels, keeping glucose amounts within a safe range -- effectively reversing the core symptoms of diabetes.
"With FGF1, we really haven't seen hypoglycemia or other common side effects," says Salk postdoctoral research fellow Jae Myoung Suh, a member of Evans' lab and first author of the new paper. "It may be that FGF1 leads to a more 'normal' type of response compared to other drugs because it metabolizes quickly in the body and targets certain cell types."
The mechanism of FGF1 still isn't fully understood -- nor is the mechanism of insulin resistance -- but Evans' group discovered that the protein's ability to stimulate growth is independent of its effect on glucose, bringing the protein a step closer to therapeutic use.
"There are many questions that emerge from this work and the avenues for investigating FGF1 in diabetes and metabolism are now wide open," Evans says. Pinning down the signaling pathways and receptors that FGF1 interacts with is one of the first questions he'd like to address. He's also planning human trials of FGF1 with collaborators, but it will take time to fine-tune the protein into a therapeutic drug.
"We want to move this to people by developing a new generation of FGF1 variants that solely affect glucose and not cell growth," he says. "If we can find the perfect variation, I think we will have on our hands a very new, very effective tool for glucose control."
Other researchers on the study were Maryam Ahmadian, Eiji Yoshihara, Weiwei Fan, Yun-Qiang Yin, Ruth T. Yu, and Annette R. Atkins of the Salk Institute for Biological Studies; Weilin Liu, Johan W. Jonker, Theo van Dijk, and Rick Havinga of the University of Groningen; Christopher Liddle of the University of Sydney; Denise Lackey, Olivia Osborn, and Jerrold M. Olefsky of the University of California at San Diego; and Regina Goetz, Zhifeng Huang, and Moosa Mohammadi of the New York University School of Medicine.
Ronald Evans is a Howard Hughes Medical Institute investigator and is also supported by grants from the National Institutes of Health, the Leona M. and Harry B. Helmsley Charitable Trust, the Glenn Foundation for Medical Research, Ipsen/Biomeasure, CIRM, and the Ellison Medical Foundation. Other study authors received grants from the National Institutes of Health, the Australian National Health and Medical Research Council, the European Research Council, the Human Frontier Science Program, the Netherlands Organisation for Scientific Research, and the Dutch Digestive Foundation.